Sysmex Corporation ADR (OTCMKTS:SSMXY) Sees Large Decrease in Short Interest

Sysmex Corporation ADR (OTCMKTS:SSMXY) saw a significant decrease in short interest in September. As of September 30th, there was short interest totaling 135,510 shares, a decrease of 44.9% from the September 15th total of 245,925 shares. Based on an average daily trading volume, of 334,412 shares, the short-interest ratio is currently 0.4 days. Approximately 0.0% of the company’s shares are sold short.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded shares of Sysmex from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 18th. Two investment analysts have rated the stock with a Hold rating. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold”.

Sysmex Stock Performance

SSMXY stock opened at $11.60 on Friday. The stock has a market capitalization of $7.06 billion, a PE ratio of 27.62 and a beta of 1.18. The stock’s 50 day simple moving average is $11.92 and its 200 day simple moving average is $10.05. Sysmex has a 12-month low of $8.01 and a 12-month high of $12.90. The company has a current ratio of 3.40, a quick ratio of 2.53 and a debt-to-equity ratio of 0.23.

Sysmex (OTCMKTS:SSMXY) last released its quarterly earnings data on Friday, August 7th. The company reported $0.09 EPS for the quarter, topping the consensus estimate of $0.07 by $0.02. The company had revenue of $825.85 million during the quarter, compared to the consensus estimate of $741.67 million. Sysmex had a return on equity of 8.01% and a net margin of 7.62%. Sysmex has set its FY 2026 guidance at 0.382-0.382 EPS. As a group, research analysts forecast that Sysmex will post 0.41 earnings per share for the current fiscal year.

Sysmex Company Profile

Sysmex Corporation is a Japan-based healthcare technology company that develops, manufactures and distributes in vitro diagnostic products and laboratory solutions. The company is best known for its automated hematology analyzers, which are used to examine blood cells, along with related reagents, software and support services.

Its product portfolio also includes systems for hemostasis, urinalysis, clinical chemistry and immunochemistry, as well as laboratory automation and information-management solutions.